Scientists from Adelaide and the United States have made a surprising discovery about a rare form of arthritis. They found ...

The drug candidate – called vorasidenib – is a dual inhibitor of mutated IDH1 and IDH2, which is being developed for a hard-to-treat form of brain cancer called glioma. It was acquired by ...

with the total value of the deal potentially rising to $2 billion if Agios’ key pipeline candidate vorasidenib – a dual inhibitor of mutated IDH1 and IDH2 in trials for a form of brain cancer ...

They discuss the importance of molecular testing, particularly for IDH1 or IDH2 mutations and outstanding questions for treatment of patients with oligodendrogliomas and astrocytomas. Read the latest ...